Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release

Bibliography

• Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368(9550):1894-907
   PubMed Web of Science ®Google Scholar
• Valk PJ, Verhaak RG, Beijen MA, Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350(16):1617-28
   PubMed Web of Science ®Google Scholar
• Latagliata R, Bongarzoni V, Carmosino I, Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol 2006;17(2):281-5
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008;66(3):181-93
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets 2005;5(4):229-48
   PubMed Web of Science ®Google Scholar
• Davis S, Aldrich TH, Jones PF, Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87(7):1161-9
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322):55-60
   PubMed Web of Science ®Google Scholar
• Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006;312(5):630-41
   PubMed Web of Science ®Google Scholar
• Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007;5(7):655-65
   PubMed Web of Science ®Google Scholar
• Loges S, Heil G, Bruweleit M, Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005;23(6):1109-17
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Hovland R, Oyan AM, Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008;22(2):287-93
   PubMed Web of Science ®Google Scholar
• Popkov M, Jendreyko N, McGavern DB, Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res 2005;65(3):972-81
   PubMed Web of Science ®Google Scholar
• Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005;6(10):1701-11
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6(5):507-16
   PubMed Web of Science ®Google Scholar
• Aguayo A, Estey E, Kantarjian H, Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94(11):3717-21
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27(21):3557-65
   PubMed Web of Science ®Google Scholar
• Jendreyko N, Popkov M, Rader C, Barbas CF 3rd. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA 2005;102(23):8293-8
   PubMed Web of Science ®Google Scholar
• Hatfield K, Ryningen A, Corbascio M, Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 2006;119(10):2313-21
   PubMed Web of Science ®Google Scholar
• Bruserud O, Tronstad KJ, Berge R. In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum. J Cancer Res Clin Oncol 2005;131(6):377-84
   PubMed Web of Science ®Google Scholar
• Alessi DR, Cuenda A, Cohen P, PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. The Journal of biological chemistry 1995;270(46):27489-94
   PubMed Web of Science ®Google Scholar
• Joiakim A, Mathieu PA, Palermo C, The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug metabolism and disposition: the biological fate of chemicals 2003;31(11):1279-82
   PubMed Web of Science ®Google Scholar
• Nemoto S, Xiang J, Huang S, Lin A. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. The Journal of biological chemistry 1998;273(26):16415-20
   PubMed Web of Science ®Google Scholar
• Sunwoo JB, Chen Z, Dong G, Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7(5):1419-28
   PubMed Web of Science ®Google Scholar
• Ryningen A, Ersvaer E, Oyan AM, Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 2006;30(12):1531-40
   PubMed Web of Science ®Google Scholar
• Ryningen A, Bruserud O. Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects. Curr Pharm Biotechnol 2007;8(6):401-11
   PubMed Web of Science ®Google Scholar
• Bechard D, Meignin V, Scherpereel A, Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37(5):417-25
   PubMed Web of Science ®Google Scholar
• Bruserud O, Hovland R, Wergeland L, Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003;88(4):416-28
   PubMedGoogle Scholar
• Irish JM, Anensen N, Hovland R, Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 2007;109(6):2589-96
   PubMed Web of Science ®Google Scholar
• Stapnes C, Doskeland AP, Hatfield K, The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136(6):814-28
   PubMed Web of Science ®Google Scholar
• Hatfield K, Oyan AM, Ersvaer E, Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 2009;144(1):53-68
   PubMed Web of Science ®Google Scholar
• Bruserud O. Effects of endogenous interleukin 1 on blast cells derived from acute myelogenous leukemia patients. Leuk Res 1996;20(1):65-73
   PubMed Web of Science ®Google Scholar
• Bruserud O, Ryningen A, Olsnes AM, Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007;92(3):332-41
   PubMed Web of Science ®Google Scholar
• Bruserud O, Tore Gjertsen B, Brustugun OT, Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia 1995;9(11):1910-20
   PubMed Web of Science ®Google Scholar
• Olsnes AM, Ersvaer E, Ryningen A, The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 2009;145(6):761-74
   PubMed Web of Science ®Google Scholar
• Martin V, Liu D, Fueyo J, Gomez-Manzano C. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 2008;23(6):773-80
   PubMed Web of Science ®Google Scholar
• Niu Q, Perruzzi C, Voskas D, Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther 2004;3(4):402-5
   PubMed Web of Science ®Google Scholar
• Valenzuela DM, Griffiths JA, Rojas J, Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999;96(5):1904-9
   PubMed Web of Science ®Google Scholar
• Saharinen P, Kerkela K, Ekman N, Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 2005;169(2):239-43
   PubMed Web of Science ®Google Scholar
• Gale NW, Thurston G, Hackett SF, Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002;3(3):411-23
   PubMed Web of Science ®Google Scholar
• Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001;49(3):659-70
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284(5422):1994-8
   PubMed Web of Science ®Google Scholar
• Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153(5):1459-66
   PubMed Web of Science ®Google Scholar
• Zagzag D, Hooper A, Friedlander DR, In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999;159(2):391-400
   PubMed Web of Science ®Google Scholar
• Pitera JE, Woolf AS, Gale NW, Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient mice. Am J Pathol 2004;165(6):1895-906
   PubMed Web of Science ®Google Scholar
• Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells: the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001;19(1):1-11
   PubMed Web of Science ®Google Scholar
• Glenjen N, Hovland R, Wergeland L, The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. Eur J Haematol 2003;71(3):163-73
   PubMed Web of Science ®Google Scholar
• Riccioni R, Diverio D, Mariani G, Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts. Stem Cells 2007;25(8):1862-71
   PubMed Web of Science ®Google Scholar
• Bruserud O, Ryningen A, Wergeland L, Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004;89(4):391-402
   PubMedGoogle Scholar
• Tomida M, Saito T. The human hepatocyte growth factor (HGF) gene is transcriptionally activated by leukemia inhibitory factor through the Stat binding element. Oncogene 2004;23(3):679-86
   PubMed Web of Science ®Google Scholar
• Hampson P, Chahal H, Khanim F, PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005;106(4):1362-8
   PubMed Web of Science ®Google Scholar
• Le Quement C, Guenon I, Gillon JY, MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008;294(6):L1076-84
   PubMed Web of Science ®Google Scholar